<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169022</url>
  </required_header>
  <id_info>
    <org_study_id>P/2018/402</org_study_id>
    <nct_id>NCT04169022</nct_id>
  </id_info>
  <brief_title>AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells</brief_title>
  <acronym>CAR-LAM</acronym>
  <official_title>Targeting Interleukin 1 Receptor Accessory Protein (IL1RAP) Expressing Acute Myeloid Leukemic (AML) Cells by Chimeric Antigen Receptor (CAR) Engineered T-cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AML is one of the most aggressive forms of leukemia, where bone marrow transplantation
      remains the gold standard treatment, with its known associated toxicities and related
      mortality. Despite progress in the treatment of leukemic malignancies, especially the
      emergence of targeted- and immuno-therapies arising from biological genomic knowledge, there
      remains a need to provide additional strategies for refractory/relapsing (R/R) patients

      Aim of this study is to collect biological samples of AML patients in order to validate our
      Chimeric Antigen Receptor T-cells immunotherapy approach
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL1RAP protein expression</measure>
    <time_frame>2 years</time_frame>
    <description>Cytometry analysis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>AML patients at diagnosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML patients at diagnosis (except AML3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AML patients at relapse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML patients at relapse after chemotherapy, targeted therapy or allograft</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>Sample collection blood and/or bone marrow</description>
    <arm_group_label>AML patients at diagnosis</arm_group_label>
    <arm_group_label>AML patients at relapse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML patients adults and pediatrics

        Exclusion Criteria:

          -  AML3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe FERRAND, PHD</last_name>
    <phone>+333381618517</phone>
    <email>christophe.ferrand@efs.sante.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BERCEANU Ana, MD</last_name>
      <email>aberceanu@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Chimeric Antigen Receptor T Cells</keyword>
  <keyword>Immunotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

